Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: An analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments

Journal of Clinical Oncology

Volumn 20, Issue 1, 2002, Pages 231-236

  Bessell, E M ^a   Lopez Guillermo A ^a   Villa S ^a   Verger, E ^a   Nomdedeu, B ^a   Petit, J ^a   Byrne, P ^a   Montserrat, E ^a   Graus, F ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; METHOTREXATE; VINCRISTINE;

ADULT; AGE; AGED; ALOPECIA; ARTICLE; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; FOLLOW UP; HEALTH STATUS; HUMAN; INTERMETHOD COMPARISON; LYMPHOMA; MALE; MULTIVARIATE ANALYSIS; NEUTROPENIA; PERFORMANCE; PHASE 2 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; RADIATION DOSE; RISK ASSESSMENT; TREATMENT OUTCOME;

ACTUARIAL ANALYSIS; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARMUSTINE; CENTRAL NERVOUS SYSTEM DISEASES; CENTRAL NERVOUS SYSTEM NEOPLASMS; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; FEMALE; GREAT BRITAIN; HUMANS; LYMPHOMA; MALE; METHOTREXATE; MIDDLE AGED; RADIOTHERAPY DOSAGE; SPAIN; SURVIVAL RATE; VINCRISTINE;

EID: 0036139049     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.20.1.231     Document Type: Article

References (25)

1. Primary CNS lymphoma
2. Therapeutic management of primary central nervous system lymphoma: Lessons from prospective trials
3. Non-Hodgkin's lymphoma of the brain: Can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG 83-15)
4. Long-term: Survival in primary CNS lymphoma
5. Treatment for primary CNS lymphoma: The next step
6. Therapy of primary CNS lymphoma with methotrexate-based chemotherapy and deferred radiotherapy: Preliminary results
7. Primary non-Hodgkin's lymphoma of the CNS treated with BVAM or CHOD/BVAM chemotherapy before radiotherapy
8. CHOD/BVAM regimen plus radiotherapy in patients with primary CNS lymphoma
9. Response criteria for phase II studies of supratentorial malignant glioma
10. Non-parametric estimation from incomplete observations
11. 2/E in the log-rank test for survival data or tumour incidence data
12. Regression models and life tables
13. Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients
14. Chemotherapy as first treatment for primary malignant non-Hodgkin's lymphoma of the central nervous system, preliminary data
15. Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma
16. High dose methotrexate for the treatment of primary cerebral lymphomas: Analysis of survival and late neurologic toxicity in a retrospective series
17. A Medical Research Council randomized trial in patients with primary cerebral non-Hodgkin lymphoma
18. The C5R Protocol: A regimen of high-dose chemotherapy and radiotherapy in primary cerebral non-Hodgkin's lymphoma of patients with no known cause of immunosuppression
19. Therapy of primary central nervous system lymphoma with pre-irradiation methotrexate, cyclophosphamide, doxorubicin, vincristine, and dexamethasone (MCHOD)
20. Short intensive primary chemotherapy and radiotherapy in sporadic primary CNS lymphoma
21. Pre-irradiation methotrexate chemotherapy of primary central nervous system lymphoma: Longterm outcome
22. Phase II multicentric study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma
23. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate and high-grade non-Hodgkin lymphoma
24. Chemotherapy without irradiation: A novel approach for newly diagnosed CNS germ cell tumors - Results of an international cooperative trial
25. Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: Response to therapy and quality of life of patients